Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Instituto Di Richerche Di Biologia Molecolare P. Angeletti Spa

Domenico Lazzaro

Gennaro Ciliberto

Nicola La Monica

Luigi Aurisicchio

Daniela Peruzzi

Federica Mori

Riccardo Cortese

Ralph Laufer

Annalise Di Marco

Giacomo Paonessa

Isabelle Gloaguen

Anna De Martis

Patrizia Costa

Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid encoding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy.

Matrix metalloproteinase 11 vaccine

The present invention refers to the use of hCNTF (human ciliary neurotrophic factor), mutants thereof or other molecules that activate the CNTF receptor, for the preparation of drugs for the treatment of obesity and associated disease, for example hyperglycemia. FIG. shows the anti-obesity effect of hCNTF and leptin on body weight (left panels) and on food intake (right panels) in genetically obese mice and in mice with diet-induced obesity (DIO).

Use of CNTF (ciliary neurotrophic factor) receptor activators for the treatment of obesity

Growing community of inventors

Rome, Italy

Domenico Lazzaro